ESR1 and breast cancer: Since the relatively limited number of pre-clinical in vivo models fails to recapitulate the multiple potential mechanisms of ER-dependent resistance, nor the profound heterogeneity that exists across ER+ breast cancer patients, we feel that this is a question that will ultimately be addressed in the clinic, as we gain additional experience with GDC-0810 and other SERDs.